Edition:
United Kingdom

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

12.53USD
20 Apr 2018
Change (% chg)

$-0.41 (-3.17%)
Prev Close
$12.94
Open
$12.90
Day's High
$12.95
Day's Low
$12.48
Volume
25,227
Avg. Vol
55,137
52-wk High
$19.50
52-wk Low
$10.26

Chart for

About

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and... (more)

Overall

Beta: -0.09
Market Cap(Mil.): $427.87
Shares Outstanding(Mil.): 25.51
Dividend: --
Yield (%): --

Financials

  OXFD.OQ Industry Sector
P/E (TTM): -- 148.40 32.74
EPS (TTM): -1.49 -- --
ROI: -39.14 9.37 14.38
ROE: -50.71 14.69 16.07

BRIEF-Oxford Immunotec Q4 Earnings Per Share $0.33

* OXFORD IMMUNOTEC REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage:

01 Feb 2018

BRIEF-Oxford Immunotec Announces Preliminary Revenue For Q4

* FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S

08 Jan 2018

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

15 Dec 2017

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

21 Nov 2017

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

31 Oct 2017

Competitors

Earnings vs. Estimates